The Top Doctors in Westchester County Offer Expert Care in 2023

Image
bidmc podiatry :: Article Creator BIDMC Podiatric Surgeon Shares Simple Tips For Keeping The Feet Healthy It's no surprise that healthy feet are important for feeling good and staying active. With 26 bones, 33 joints and more than 100 muscles, tendons and ligaments, the foot is one of the most complex parts of the skeletal system. BIDMC podiatric surgeon Thanh Dinh, DPM, shares five simple tips for keeping your feet feeling their best. Dry off from head to toe. You likely towel off after each shower, but do you thoroughly dry your feet? "Excess moisture that can get trapped in socks and between toes makes it easy for a fungal infection to begin," says Dinh. Trim nails regularly. Pedicures are nice, but all you really need is a straight cut across each nail, without trimming too close to the skin. "A straight cut helps deter painful ingrown toenails," she says. Wear shoes that fit. Shoes that are too big or too s...

CDC Panel Votes to Recommend Shingrix for Immunocompromised Adults - Monthly Prescribing Reference

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of herpes zoster (shingles) and its complications in adults 19 years of age and older who are, or will be immunodeficient or immunosuppressed due to disease or therapy.

Shingrix is intended for intramuscular injection in 2 doses separated by 2 to 6 months in immunocompetent adults. In adults who are or will be immunodeficient or immunosuppressed due to known disease or therapy and who would benefit from a shorter vaccination schedule, the second dose may be administered 1 to 2 months after the first dose.

The recommendation was based on data from clinical studies that assessed the efficacy and safety of Shingrix in adults 18 years of age and older who previously had an autologous hematopoietic stem cell transplant (auHSCT; N=1721) and in those undergoing treatment for hematologic malignancies (N=515; post-hoc analysis).

Shingrix was found to be 68.2% (95% CI, 55.5-77.6) effective against the development of herpes zoster in immunocompromised adults who received an auHSCT 50 to 70 days prior to the first dose and who were expected to receive prophylactic antiviral therapy for at most 6 months post-transplant. In the hematologic malignancy study, post hoc analysis showed Shingrix was 87.2% (95% CI, 44.2-98.6) effective against herpes zoster development.

The approval was further supported by safety and immunogenicity data in adults who were, or were anticipated to be immunodeficient or immunosuppressed due to known disease or therapy, including patients with HIV, solid tumors, and renal transplants.

The recommendations will be reviewed for approval by the director of the CDC and the US Department of Health and Human Services. Following approval, the final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR).

"Today's recommendation is an important clinical advancement in providing protection from shingles and its complications to adults with immunodeficiency or immunosuppression," said Sabine Luik, Chief Medical Officer & SVP Global Medical Regulatory & Quality, GSK. "The ACIP's vote helps to address an existing unmet need as individuals who are immunocompromised are at an increased risk of the disease."

Shingrix is currently approved for the prevention of herpes zoster in adults 50 years of age and older. It is also approved for the prevention of herpes zoster in adults 18 years of age and older who are or who will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.

Reference

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up. News release. GlaxoSmithKline. October 20, 2021. Accessed October 21, 2021. https://www.gsk.com/en-gb/media/press-releases/votes-unanimously-to-recommend-shingrix-for-immunocompromised-adults-aged-19-and-up/. 

Comments

Popular posts from this blog

180+ chief medical officers to know | 2025

Primary Care - North Greece Internal Medicine & Pediatrics

Screening and Testing for Hepatitis B Virus Infection ...